Lexicon Pharmaceuticals

Latest news

• FDA Approves Inpefa (sotagliflozin) for the Treatment of Heart Failure
  27 May 2023
• Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
  27 July 2022
• Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
  31 May 2022
• Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
  28 February 2022
• Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults with Type 2 Diabetes
  30 December 2021
• Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure
  14 January 2021
• FDA Issues Complete Response Letter for Zynquista (sotagliflozin)
  25 March 2019
• FDA Advisory Committee Votes on Zynquista (sotagliflozin) as Treatment for Adults with Type 1 Diabetes
  17 January 2019
• FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes
  22 May 2018
• Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes
  26 March 2018

Drugs Associated with Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.